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Abstract
Background: Previously it has been shown that insulin-mediated tyrosine phosphorylation of
myosin heavy chain is concomitant with enhanced association of C-terminal SRC kinase during
skeletal muscle differentiation. We sought to identify putative site(s) for this phosphorylation event.
Results: A combined bioinformatics approach of motif prediction and evolutionary and structural
analyses identified tyrosines163 and 1856 of the skeletal muscle heavy chain as the leading candidate
for the sites of insulin-mediated tyrosine phosphorylation.
Conclusion:  Our work is suggestive that tyrosine phosphorylation of myosin heavy chain,
whether in skeletal muscle or in platelets, is a significant event that may initiate cytoskeletal
reorganization of muscle cells and platelets. Our studies provide a good starting point for further
functional analysis of MHC phosphor-signalling events within different cells.
Introduction
Myosins, actin-based motor proteins, are expressed as
multiple isoforms in all eukaryotic cells. They are oligom-
ers consisting of one or two heavy chains to which one or
more light chains are non-covalently attached. Myosins
have been classified into 18 families based on the amino
acid sequence differences in the N-terminal head
domains, which contain highly conserved regions includ-
ing actin- and nucleotide-binding sites [1,2]. The tail of
myosin is the most variable domain and seems to be
responsible for the specific role myosin plays in the cell.
Functional activities of most myosins such as actin-
dependent ATPase activity or ability to move actin fila-
ments in vitro are regulated in several ways, mainly by
phosphorylation of the regulatory light chain, Ca2+-bind-
ing, or phosphorylation of the heavy chain [1,3] It has
been previously claimed that the myosin heavy chain
(MHC)undergoes tyrosine phosphorylation during insu-
lin-mediated skeletal muscle differentiation, thus linking
signal transduction to highly ordered myosin assembly
[4]. Insulin modulates an association of myosin with C-
terminal SRC kinase (Csk), a tyrosine kinase signalling
molecule, and these interactions are fundamental in skel-
etal muscle differentiation. Although the claims of tyro-
sine phosphorylation of MHC in vivo remain somewhat
controversial, tyrosine phosphorylation of non-muscle
MHC IIa has also been implicated as an early event in
human platelet activation [5]. To settle this controversy -
and establish the role, if any, of MHC tyrosine phosphor-
ylation it is important to identify sites at which such phos-
phorylation events may occur.
We have mapped potential phosphorylation sites on the
skeletal muscle myosin heavy chain utilizing an integrated
bioinformatics approach, supporting web-based motif
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predictions with evolutionary and structural data. Of all
the sites analyzed in the bioinformatics approach, the
data suggest Y163 and Y1856 as the leading candidates for
insulin-mediated tyrosine phosphorylation.
Methods
Tyrosine Phosphorylation Predictions
Tyrosine phosphorylation site predictions were made
with two different online resources using the sequences
described below. NetPhos 2.0 produces neural network
predictions based on sequence and structure [6]. Scansite
predicts target motifs for different kinases using a posi-
tional selectivity matrix based on peptide library screening
data [7,8] In addition, Scansite predictions were made for
known phosphotyrosine recognition motifs for evidence
of downstream signalling events. All Scansite predictions
were made on the 'Low Stringency' setting to identify as
many putative sites as possible. These sites were then sup-
ported or rejected on the basis of further analysis as
described below.
Evolutionary Analysis
Protein sequences for adult skeletal muscle myosin heavy
chains (MYHSA) 1 and 2 were extracted from the Swiss-
Prot database [9] MYHSA1 [SwissProt : MYH1_HUMAN,
P12882]; MYHSA2 [SwissProt ID: MYH2_HUMAN,
Q9UKX2] and used as query sequences to extract closely
related homologous proteins. First, BLAST [10] was used
to search SwissProt-TrEMBL [9] and the known, novel and
Genscan-predicted peptides of five EnsEMBL genome
databases (Human, Mouse, Rat, Fugu, Zebrafish) [11]
Redundant sequences were removed and ALIGN [12,13]
was used to make pairwise alignments of each homologue
with MYH1_HUMAN and to calculate the percentage
identity across the entire length of the protein. Vertebrate
homologues with at least 60% global identity were proc-
essed using an in-house homologue processing tool,
HAQESAC [14]. Homologues were aligned using CLUS-
TALW [15] and badly-aligned sequences eliminated from
the dataset. A neighbour-joining tree with 1000 bootstrap
replicates was constructed using CLUSTALW and the
sequences were grouped into subfamilies of orthologous
proteins. The clade corresponding to skeletal muscle
myosin heavy chains in Amniota (mammals, reptiles and
birds) were then used as sequences for tyrosine phospho-
rylation motif prediction as described above.
Secondary Structure Prediction
Secondary structure predictions were made for
MYH1_HUMAN using the PSIPRED V2.3 website [16].
Because of the length of the protein, it was submitted in
two overlapping chunks: residues 1–814 and 800 +.
3D Structure Analysis
3D structures were obtained from the Protein Data Bank
(PDB) [17] and viewed with the RasMol viewer [18].
Three myosin heavy chain structures were identified:
2MYS, Chicken adult skeletal muscle myosin heavy chain;
1BR2, chicken gizzard smooth muscle myosin heavy
chain; and 1B7T, Aequipecten irradians (Bay scallop) stri-
ated muscle myosin heavy chain. The corresponding
SwissProt sequences [Swiss -Prot :2MYS: MYSS_CHICK,
P13538]; [Swiss-Prot1BR2: MYHB_CHICK, P10587];
[Swiss -Prot1B7T: MYS_AEQIR, P24733] were down-
loaded and aligned with Human MYH1_HUMAN and
MYH2_HUMAN using CLUSTALW. This alignment was
used with the skeletal muscle myosin heavy chains
(above) to assign putative tyrosine phosphorylation sites
to their corresponding residues in the homologous 3D
structures. Visualisation with RasMol and DSSP solvent
accessibility data [19] was then used to infer whether
potential sites of tyrosine phosphorylation were surface-
exposed or buried.
Results
In total, twenty-three myosin heavy chain sequences were
used for tyrosine phosphorylation motif prediction,
which were divided into five groups of orthologous
sequences (Figure 1). Important motifs are likely to be
conserved during evolution and so we considered only
those sites that were predicted to be phosphorylation
motifs in all the sequences of at least one orthologous
group. Because phosphorylation site predictors have a
tendency to over-predict, we increased stringency by
accepting only those motifs that received a NetPhos score
of 0.8 or higher, or were predicted by both NetPhos and
Scansite, in at least one human adult skeletal myosin
heavy chain. This yielded fourteen putative sites (Table 1).
Of these, six were predicted by both methods, including
two motifs that were conserved across all sequences
(MYH1_HUMAN Y163 and Y1856).
To be phosphorylated, tyrosine residues must be accessi-
ble on the surface of the protein. Although the three-
dimensional conformations of homologous myosin mol-
ecules will not be identical, the high degree of sequence
conservation between human adult skeletal muscle
myosin heavy chains and the three myosin sequences
present in PDB allowed the inference of solvent accessibil-
ity. This was confirmed by the generally good agreement
in surface accessibility measures both between models
and between the different myosin chains of 1BR2 (data
not shown). From these data, two sites (Y286 and Y435)
were buried while a further two (Y313 and Y504) had very
low solvent accessibility (Table 1). 3D data were not avail-
able for the four tyrosines in the C-terminal of the protein.Theoretical Biology and Medical Modelling 2005, 2:12 http://www.tbiomed.com/content/2/1/12
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Neighbour-joining phylogeny of MHC homologues, with bootstrap support Figure 1
Neighbour-joining phylogeny of MHC homologues, with bootstrap support. PDB structure 2MYS is marked with a black 
diamond.
Table 1: Summary of predicted tyrosine phosphorylation sites.
Sitea NetPhosb Scansitec 2Dd Surface Accessibilitye
MYH1 MYH4 MYH2 MYH8 MYSS_
CHICK
MYH3_
CHICK
MYH3 MYH1 MYH4 MYH2 MYH8 MYSS_
CHICK
MYH3_
CHICK
MYH3 MYH1 1BR2 1B7T:A 2MYS: 
A
Mean
47 - - - Y - - - E(4) (14.5) (21) (16) 18.5
5 4 ------Y------ E ( 7 ) ( 5 2 ) ( 6 0 ) 5 6 . 0
8 5YYYYYYY C ( 2 ) ( 3 4 . 7 ) ( 2 8 ) 1 6 2 6 . 2
1 6 3 YYYYYYY Y P Y P Y P Y P Y P Y P Y P H ( 9 ) 1 3 . 3 4 78 2 2 . 8
2 8 6 YYYYYYY YY H ( 7 ) ( 0 ) 00 0 . 0
313 Y - YP - Y Y YP Y Y C(4) 7 5 8 6.7
413 Y Y Y Y - Y Y - E(7) (68) 68.0
435 - Y - H(9) (0.7) 4 3 2.6
5 0 4 YYYYYYY H ( 9 ) 069 5 . 0
719 Y Y Y Y Y YP YP YP YP YP YP Y H(6) (21.8) 19 9 16.6
1 3 7 9 YYYYYYY H ( 6 )
1464 - Y - Y Y Y - - - - H(7)
1 4 9 2 YYYYYYY Y P P H ( 6 )
1 8 5 6 YYYYYYYYYYYYYY H ( 4 )
a. Sites are numbered relative to the MHC sequence MYH1_HUMAN/P12882.
b. Y indicates predicted tyrosine phosphorylation site in all the sequences of orthologous group, with a score of ≥  0.8 in at least one human sequence. 
Dashes indicate lack of a tyrosine in that position.
c. Y indicates predicted tyrosine phosphorylation site in all the sequences of orthologous group on 'Low Stringency'. P indicates predicted 
phosphotyrosine recognition site in all the sequences of orthologous group on 'Low Stringency'. Dashes indicate lack of a tyrosine in that position.
d. PSIPRED (McGuffin, Bryson and Jones 2000) secondary structure position for MYH1_HUMAN. Letters indicate predicted secondary structure (H 
= helix, E = strand, C = coil). Numbers in brackets are confidence measures (0 = low, 9 = high).
e. Surface accessibility figures are "numbers of water molecules in contact with this residue *10, or residue water exposed surface in Angstrom**2" 
(Kabsch and Sander 1983). Missing values indicate residues missing from the PDB structure. Values in brackets indicate residues that are not tyrosines 
in the PDB structure.
MYH3 HUMAN/P11055 Myosin heavy chain fast skeletal muscle embryonic
myh3 PANTR/ENSPTRP00000014947 pepknown
MYH3 RAT/P12847 Myosin heavy chain fast skeletal muscle embryonic
myh3 MOUSE/ENSMUSP00000007301 pepnovel
MYH3 CHICK/P02565 Myosin heavy chain fast skeletal muscle embryonic
MYSS CHICK/P13538 Myosin heavy chain skeletal muscle adult
MYH8 HUMAN/P13535 Myosin heavy chain skeletal muscle perinatal
MYH2 HUMAN/Q9UKX2 Myosin heavy chain skeletal muscle adult2
myh2 PANTR/ENSPTRP00000014942 pepknown
myh2 BOVIN/Q9BE41 Myosin heavy chain 2a
myh2 PIG/Q9TV63 Myosin heavy chain 2a
myh2 EQUPR/Q8MJV1 Myosin heavy chain 2a
myh2 MOUSE/Q922D2 Similar to myosin heavy polypeptide 2 skeletal muscle adult
myh2 RAT/ENSRNOP00000004236 pepnovel
MYH4 HUMAN/Q9Y623 Myosin heavy chain skeletal muscle 2b fetal
myh4 PIG/Q9TV62 Myosin heavy chain 2b
MYH1 HUMAN/P12882 Myosin heavy chain skeletal muscle adult 1 'MyHC-2x/d'
myh1 PANTR/ENSPTRP00000014940 pepknown
myh1 RAT/ENSRNOP00000004295 pepnovel
MYH4 RABIT/Q28641 Myosin heavy chain skeletal muscle juvenile
myh1 PIG/Q9TV61 Myosin heavy chain 2x
myh1 BOVIN/Q9BE40 Myosin heavychain 2x
myh1 EQUPR/Q8MJV0 Myosin heavy chain 2x
Fish Outgroup
1000
991
997
1000
1000
1000
695
614
1000
395
1000
974
1000
688
578
622
682
879
983
655
960
1000
816
0.02Theoretical Biology and Medical Modelling 2005, 2:12 http://www.tbiomed.com/content/2/1/12
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If tyrosine phosphorylation of MMHC-II is part of a sig-
nalling cascade, it is likely that some other protein will
interact with the phosphotyrosine. We used Scansite to
look for phosphotyrosine interaction motifs and found
three SH2 domain recognition motifs that matched
potentially exposed phosphorylation sites. Because
Scansite also identifies the interacting protein, we interro-
gated the Gene Cards [20] entry for each kinase and SH2
domain for expression patterns. Only four kinases and
two SH2 domains had evidence from UniGene [21] or
SAGE [22] of expression in skeletal muscle, while only
one kinase (INSR) and one SH2 domain (PIK3R1) had
evidence from both (Table 2). Interestingly, both of the
latter pair were predicted to interact with the same, totally
conserved, motif (MYH1_HUMAN Y163). Furthermore,
both are involved in insulin-mediated pathways (see Dis-
cussion). Two kinases expressed in skeletal muscle were
predicted to interact with Y1856. These were an SRC
kinase and ABL1, which interacts with SORBS1 following
insulin stimulation [23].
Discussion
Bioinformatics alone cannot identify a functional motif;
supporting experiments will always be needed for conclu-
sive evidence. Nevertheless, while other sites cannot be
categorically excluded, the combined data presented here
identify Y163 and Y1856 as the most likely sites for tyro-
sine phosphorylation events in skeletal muscle. Both Net-
Phos and Scansite predicted these motifs for all
mammalian adult skeletal myosin heavy chain sequences
analysed, indicating strong evolutionary conservation
(Figure 1). A kinase predicted to be responsible for phos-
phorylation of each site is expressed in skeletal muscle, as
was an SH2 domain protein that was predicted to interact
Table 2: Interacting enzymes predicted by Scansite.
Sitea Enzymeb Gene Card UniGenec SAGEc Full Name
163 EGFR Kinase EGFR Yes No EGFR (epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-
b) oncogene homolog, avian))
Insulin Receptor Kinase INSR Yes Yes INSR (insulin receptor)
p85 SH2 PIK3R1 Yes Yes PIK3R1 (phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 
alpha))
Shc SH2 SHC1 No No SHC1 (SHC (Src homology 2 domain containing) transforming protein 1)
286 EGFR Kinase EGFR Yes No EGFR (epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-
b) oncogene homolog, avian))
313 EGFR Kinase EGFR Yes No EGFR (epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-
b) oncogene homolog, avian))
Fgr Kinase FGR No No FGR (Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog)
PDGFR Kin PDGFRB No Yes PDGFRB (platelet-derived growth factor receptor, beta polypeptide)
Itk SH2 ITK No No ITK (IL2-inducible T-cell kinase)
Fgr SH2 FGR No No FGR (Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog)
719 Lck Kinase LCK No No LCK (lymphocyte-specific protein tyrosine kinase)
Abl Kinase ABL1 No Yes ABL1 (v-abl Abelson murine leukemia viral oncogene homolog 1)
Itk SH2 ITK No No ITK (IL2-inducible T-cell kinase)
Src Kinase SRC Yes No SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian))
149
2
Src Kinase SRC Yes No SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian))
Lck SH2 LCK No No LCK (lymphocyte-specific protein tyrosine kinase)
Fgr SH2 FGR No No FGR (Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog)
Src SH2 SRC Yes No SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian))
185
6
Lck Kinase LCK No No LCK (lymphocyte-specific protein tyrosine kinase)
Src Kinase SRC Yes No SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian))
Abl Kinase ABL1 No Yes ABL1 (v-abl Abelson murine leukemia viral oncogene homolog 1)
a. Sites are numbered relative to the MHC sequence MYH1_HUMAN/P12882.
b. Enzyme identified by Scansite.
c Skeletal muscle expression data from GeneCards (Rebhan et al. 1997).Theoretical Biology and Medical Modelling 2005, 2:12 http://www.tbiomed.com/content/2/1/12
Page 5 of 6
(page number not for citation purposes)
with a phosphotyrosine at Y163. Analysis of predicted sec-
ondary structures and homologous 3D structures indi-
cates that these sites may be accessible on the protein
surface. The position of Y163 as part of an alpha helix
within the globular myosin head domain does raise con-
cerns that it is potentially difficult to phosphorylate, even
though it is on the surface of the domain. Nevertheless,
depending on the relative conformations of the solved in
vitro  chicken myosin structures compared to in vivo
human myosin, Y163 might still be available for phos-
phorylation. Y1856 is in region of low predicted second-
ary structure (Table 1), indicative of a flexible loop region
more usually associated with phosphorylation sites.
Myosin heavy chain (MHC) undergoes tyrosine phospho-
rylation during insulin-mediated differentiation in skele-
tal muscles and the degree of phosphorylation increases
in line with differentiation [4]. Interestingly, for the
strongest candidate tyrosine phosphorylation site, Y163,
both the kinase and interacting SH2 domain predicted by
Scansite are involved in insulin-mediated pathways. The
kinase INSR is a transmembrane receptor that binds insu-
lin [24] while the SH2 domain protein PIK3R1 is neces-
sary for the insulin-stimulated increase in glucose uptake
and glycogen synthesis in insulin-sensitive tissues [25].
We can therefore conclude that Y163 remains a strong
candidate site for insulin-mediated tyrosine phosphoryla-
tion of myosin heavy chain, despite concerns over
accessibility.
As phosphorylation sites are often in the tails of proteins,
the tyrosines outside the main globular domains, namely
Y1379, Y1492 and Y1856, are also potential candidates
for phosphorylation. The strongest of these is Y1856,
which is both C-terminal and predicted to be phosphor-
ylated by the kinases SRC and ABL1, which are found in
skeletal muscle (Table 2). Perhaps of most interest is
ABL1, a protein known to be associated with "Sorbin and
SH3 domain containing 1" (SORBS1) during insulin sig-
nalling in other cell lines [23]. SORBS1 is highly expressed
in skeletal muscle (data not shown) and is involved in for-
mation of actin stress fibres and focal adhesions; its ortho-
logue, CAP, has been identified as an important adaptor
during insulin signalling in mice [26-28]. Furthermore,
the SORBS1 gene has been implicated in the pathogenesis
of human disorders with insulin resistance [29].
Csk has been shown to be associated with the hormone 1,
25(OH)2-vitamin D3 resulting in the stimulation of the
growth-related mitogen-activated protein kinase (MAPK).
The phosphorylated form of MAPK is then translocated to
the nucleus where it induces the expression of c-myc
oncoprotein associated with skeletal muscle proliferation
[30]. In addition, Csk has also been implicated in the reg-
ulation of integrins and the control of cell attachment and
shape [31] Goel et al. showed that insulin can phosphor-
ylate myosin, leading to an association with Csk and thus
to a decrease in c-Src activity. This has also been shown in
fibroblast cell lines following stimulation of the insulin-
like growth factor-I receptor [32]. This demonstrates the
potential for skeletal muscle differentiation after phos-
phorylation of Y163 and/or Y1856 of the MHC.
Harney et al. have shown that non-muscle myosin heavy
chain type IIA in platelets undergoes tyrosine phosphor-
ylation and subsequent dephosphorylation in a time-
dependent manner [5]. In common with other cells, the
cytoskeleton of platelets comprises actin filaments, micro-
tubules and myosin molecules. Myosins form rings within
the platelet that maintain a spherical shape and several
lines of evidence suggest that these rings reorient follow-
ing platelet activation to permit spreading [33,34]. While
myosin function therefore appears critical to platelet
spreading, studies using cytoskeleton inhibitors have
shown that at least the early events of platelet activation
are not dependent on the cytoskeletal changes [35]. Our
work is suggestive that tyrosine phosphorylation of
myosin heavy chain, whether in skeletal muscle or in
platelets, is a significant event that may initiate cytoskele-
tal reorganization of muscle cells and platelets. Our stud-
ies provide a good starting point for further functional
analysis of MHC phosphor-signalling events within differ-
ent cells.
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